Clinical Trials
96 trialsNCT06380816 2026-05-08
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Phase 1/2 Recruiting
NCT07509008 2026-05-05
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07529613 2026-04-14
T-DXd_HER2Low
National Cancer Center Hospital East
Phase 1/2 Completed
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT03539822 2026-01-21
CAMILLA
University of Pittsburgh
Phase 1/2 Recruiting
NCT07333573 2026-01-12
A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Phase 1/2 Not yet recruiting
NCT06085755 2025-12-15
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Samsung Medical Center
Phase 1/2 Recruiting
NCT07149090 2025-11-20
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
Asan Medical Center
Phase 1/2 Recruiting
NCT06759064 2025-11-19
IPIZA
Qilu Hospital of Shandong University
Phase 1/2 Recruiting
NCT05438459 2025-11-18
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
Kyushu University
Phase 1/2 Recruiting
NCT00722228 2025-10-02
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT05057013 2025-08-11
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Phase 1/2 Active not recruiting
NCT07108855 2025-08-07
BRIGHT
University Medical Center Groningen
Phase 1/2 Recruiting
NCT06732856 2025-07-28
NEO-CLAUD
Asan Medical Center
Phase 1/2 Recruiting
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04592211 2025-07-11
Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
Yonsei University
Phase 1/2 Recruiting
NCT05894824 2025-07-11
T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Yonsei University
Phase 1/2 Recruiting
NCT04963088 2025-06-26
TALENT
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2 Completed
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT07025889 2025-06-18
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Ruijin Hospital
Phase 1/2 Recruiting
NCT06766305 2025-06-17
QL1706 Combined With SOX Used in Theperioperative Treatment
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting
NCT06742411 2025-05-07
XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
West China Hospital
Phase 1/2 Recruiting
NCT06940921 2025-04-27
SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases
First Affiliated Hospital of Chongqing Medical University
Phase 1/2 Active not recruiting
NCT04166721 2025-04-06
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
Royal Marsden NHS Foundation Trust
Phase 1/2 Active not recruiting
NCT06871527 2025-03-12
Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06776770 2025-01-15
GC-Ib/II
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1/2 Recruiting
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT06532799 2024-11-12
BAH250
Essen Biotech
Phase 1/2 Recruiting
NCT03453164 2024-09-19
Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)
Fukushima Medical University
Phase 1/2 Completed
NCT05187338 2024-06-25
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2 Recruiting
NCT06426654 2024-05-23
Sintilimab Combined With LDRT for Neoadjuvant Treatment of Locally Advanced dMMR/MSI-H Gastric Cancer
West China Hospital
Phase 1/2 Not yet recruiting
NCT04835896 2024-05-06
Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer
Yonsei University
Phase 1/2 Completed
NCT05101616 2024-03-07
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
Shanghai Minimally Invasive Surgery Center
Phase 1/2 Suspended
NCT03751761 2024-02-28
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
Asan Medical Center
Phase 1/2 Completed
NCT06266871 2024-02-20
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
West China Hospital
Phase 1/2 Not yet recruiting
NCT03618758 2023-12-05
IPLUS
Seoul National University Bundang Hospital
Phase 1/2 Completed
NCT05400915 2023-11-13
Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients
Yonsei University
Phase 1/2 Completed
NCT04631731 2023-06-01
ICEMELT
Western Sydney Local Health District
Phase 1/2 Unknown
NCT05640609 2023-05-16
Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
West China Hospital
Phase 1/2 Recruiting
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT03995017 2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2 Unknown
NCT05587088 2022-10-19
PA001
Hospital Universitario San Ignacio
Phase 1/2 Unknown
NCT05535569 2022-09-10
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
Yonsei University
Phase 1/2 Completed
NCT05024812 2022-08-18
Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 1/2 Unknown
NCT05439993 2022-07-05
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Hallym University Medical Center
Phase 1/2 Recruiting
NCT02562963 2022-05-02
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
Tsinghua University
Phase 1/2 Unknown
NCT05198856 2022-01-20
Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC
Qilu Hospital of Shandong University
Phase 1/2 Unknown
NCT04105062 2021-12-09
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Washington University School of Medicine
Phase 1/2 Withdrawn
NCT04526470 2021-08-24
Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer
Seoul National University Bundang Hospital
Phase 1/2 Unknown